CBtru®, an innovative drug delivery solution

Address the challenges of bioavailability, patient convenience, and compliance

Understanding the opportunity

Formulating a highly lipophilic and poorly soluble crystalline molecule, such as cannabidiol (CBD), can be a complex task. In fact, the oral bioavailability of CBD can be as low as 6% in humans, as a result of incomplete absorption in the gut and significant pre-systemic elimination in the liver.¹

This has slowed the development of patient-friendly solid oral dosage forms—until now.

Make patient-friendly CBD therapies possible with CBtru®

CBtru®, an innovative, patent-pending drug delivery solution, is making a new era in drug formulation possible—one that unlocks the true potential of highly lipophilic molecules, like CBD. Enabling optimized bioavailability in solid oral dosage forms is paving the way for more patient-friendly delivery systems, such as tablets and capsules. This will help increase patient convenience and compliance, and elevate patient care worldwide.

Oral solid dosage forms

Make oral solid dosage forms a reality—supporting enhanced patient-centricity and wider applicability.

Higher API loading

Harness three to four times higher API loading to achieve lower daily dosages and more convenience for patients.

Optimized bioavailability

CBtru® has a comparable bioavailability to the only market-approved CBD drug product, which is a liquid oil-based dosage form.

Safe and well-tolerated

Clinical research confirms that CBtru® is safe and well-tolerated in humans.

Clinical study reveals CBtru® is as good as gold-standard CBD medicine

New clinical research validates that our first-of-a-kind CBD drug product intermediate, CBtru®, offers optimized bioavailability in oral solid dosage forms, which is as good as the current gold-standard liquid oil-based CBD medicine. Plus, it may offer a more reliable and consistent uptake, less dependent on food intake.

Watch presentation

Pioneering patient-centric dosage forms with CBtru®: case study example

Discover how we joined forces with Oz Medicann Group (OMG) Pharma–-an Australian-based biotech innovator in the cannabinoid medicines domain—to create a CBD-based oral solid dosage form using CBtru®. Together, we pioneer patient-friendly orally disintegrating tablets (ODTs) for the treatment of insomnia.

Download case study

Elevated by Verilege™

CBtru® is elevated by Verilege™, a suite of expert services including quality, regulatory, sustainability, and supply chain services—and superior customer care, designed to help you navigate the market with confidence and peace of mind.

Learn more

References

1. Perucca and Bialer. Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination, and related clinical implications. Cannabinoids in Neurology and Psychiatry, 2020.

2. Millar et al. Towards better delivery of cannabidiol (CBD). Pharmaceuticals (Basel), vol. 13, pg. 219, 2020.

Ask-the-expert: What’s next for pharma regulations in Asia-Pacific?

Discover the top 5 trends transforming pharma regulations in Asia-Pacific and how drug developers can navigate this evolving landscape with dsm-firmenich.

Read more
dsm-firmenich’s API portfolio elevated by Verilege™

Simplify the drug approvals process with Verilege™, an expert services platform offering regulatory, quality, sustainability, and supply chain support for APIs.

Read more
Introducing dsm-firmenich’s new portfolio of taste solutions for pharmaceutical formulations

Discover our novel portfolio offering for the pharmaceutical market, which aims to address a growing need for full-service flavor solutions and taste modulation strategies.

Read more